Australia markets closed

Immunovant, Inc. (IMVT)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
32.31-0.21 (-0.65%)
At close: 04:00PM EDT
32.31 0.00 (0.00%)
After hours: 04:02PM EDT
Show:
Annual

Income statement

All numbers in thousands
Breakdown
ttm
31/03/2023
31/03/2022
31/03/2021
31/03/2020
Total revenue
0
0
0
0
0
Operating expenses
Research development
198,709
160,257
101,808
68,604
47,927
Selling general and administrative
54,880
48,019
54,225
39,513
18,151
Total operating expenses
253,589
208,276
156,033
108,117
66,078
Operating income or loss
-253,589
-208,276
-156,033
-108,117
-66,078
Interest expense
-
-
-
0
625
Total other income/expenses net
-10,565
-10,253
-781
328
412
Income before tax
-244,105
-210,951
-156,814
-107,789
-66,291
Income tax expense
-656
9
-84
-358
97
Income from continuing operations
-243,449
-210,960
-156,730
-107,431
-66,388
Net income
-243,449
-210,960
-156,730
-107,431
-66,388
Net income available to common shareholders
-243,449
-210,960
-156,730
-107,431
-66,388
Basic EPS
-1.96
-1.71
-1.43
-1.22
-1.54
Diluted EPS
-1.96
-1.71
-1.43
-1.22
-1.54
Basic average shares
130,197
123,075
109,679
87,757
43,199
Diluted average shares
130,197
123,075
109,679
87,757
43,199